Tango Therapeutics is a biotechnology company focused on developing precision oncology medicines by targeting cancer vulnerabilities created by tumor suppressor gene loss. The company uses synthetic lethality approaches to identify and develop therapies that selectively kill cancer cells while sparing normal cells, particularly focusing on tumors with specific genetic alterations.
Founded in 2017, Tango Therapeutics went public via SPAC merger in 2021. The company emerged from foundational research on synthetic lethality and has built a pipeline of small molecule therapeutics targeting various cancer types. Tango operates in the competitive precision oncology space, developing treatments for genetically defined patient populations where current therapeutic options are limited.
Tango Therapeutics has received investment from 1 venture capital firm.
Tango Therapeutics develops precision oncology medicines using synthetic lethality approaches to target cancer vulnerabilities created by tumor suppressor gene loss.
Tango Therapeutics has received investment from Atlas Venture. These venture capital firms and investors provide both capital and strategic support.
Tango Therapeutics operates in the Biotech sector. Tango Therapeutics develops precision oncology medicines using synthetic lethality approaches to target cancer vulnerabilities created by tumor suppressor gene loss.
